Shanghai Fosun Pharmaceutical, coronavirus, coronavirus vaccine, Covid-19 vaccines, coronavirus vaccines, win approval

A unit of Shanghai Fosun Pharmaceutical has agreed to form a US$200 million joint venture with German partner BioNTech to build a plant in China capable of supplying as much as one billion doses of coronavirus vaccine a year.

Shanghai Fosun Pharmaceutical Industry Development will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how to produce the vaccine of the same value. Each party will own half of the venture.

“Fosun Pharmaceutical Industry shall provide a manufacturing facility, which has the potential capacity of producing up to one billion doses of coronavirus vaccine product per annum, and shall inject the manufacturing facility into the joint venture,” Fosun Pharmaceutical said in a filing to Hong Kong’s bourse late on Sunday.

Fosun will also provide loans to the planned 15-year joint venture – to be incorporated in Shanghai – of up to €150 million (US$182.4 million), besides arranging other credit facilities.

The announcement of the agreement comes as governments wrangle over whether to waive patents on Covid-19 vaccines, which will affect the value of manufacturing licences.

Germany has opposed the US-backed proposal first initiated by India and South Africa last fall, saying protection of intellectual property is key to encouraging innovation and should not be taken away.

Supporters, including some European Union states like France and Italy, have said it will let more companies manufacture the vaccine that is needed to save lives and bring back the global economy to normal, especially in developing nations.

Mainz, Germany-based BioNTech, a biotechnology start-up, has developed one of the most widely used and effective coronavirus vaccines to date, based on the mRNA platform.

mRNA vaccines work by introducing a molecule coded for a disease-specific protein, which can “coach” the body’s immune system to produce antibodies and generate immune responses against the virus.

Its marketing success was made possible by a partnership with US pharmaceutical giant Pfizer, which has an extensive network for clinical trials, besides strong manufacturing and sales capabilities.

Pfizer expected revenue from the vaccine to account for over a third of its sales this year, based on contracts to deliver 1.6 billion vaccine doses this year.

Fosun is BioNTech’s exclusive partner for the vaccine in mainland China, Hong Kong, Taiwan and Macau.

A Reuters report quoting BioNTech chief executive Ugur Sahin said late last month that he expected its Covid-19 vaccine to win approval from the mainland Chinese health authorities “by July at the latest”.

Some 318 million of Covid-19 vaccines have been administered in China so far, according to Our World in Data, primarily products developed by state-owned Sinopharm and privately controlled Sinovac Biotech.

The proposed joint venture’s board will have six directors, Fosun said. Fosun will nominate candidates for the positions of general manager and vice-president of finance, while BioNTech will nominate the deputy general manager and vice-president of compliance.


Japan travel news, japan travel guides, japan holiday destinations and japan reviews

LATEST NEWS

NEWS RELATED

China’s Big Tech still most attractive employer for university students despite Beijing’s scrutiny of the sector

China’s Big Tech companies remain the most attractive employers for university students across several different college majors, despite Beijing’s increased scrutiny of the sector. Huawei Technologies Co, the world’s largest telecommunications equipment vendor, and e-commerce giant Alibaba Group Holding held the top two spots as the most attractive employers to…

Read more: China’s Big Tech still most attractive employer for university students despite Beijing’s scrutiny of the sector

Vehicle finance, micro loan NBFCs collections worse hit due to Covid-induced localised lockdowns: IndiaRatings

Vehicle financing and micro finance segments of non banking finance companies (NBFCs) have been hardest hit as localised lockdowns and rising infections within staff have hit collection efficiencies raising the risk of non performing assets (NPAs), credit rating agency IndiaRatings (Ind-Ra) said. Besides the problems due to the pandemic commercial…

Read more: Vehicle finance, micro loan NBFCs collections worse hit due to Covid-induced localised lockdowns: IndiaRatings

Pfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt

Pfizer CEO Albert Bourla on June 22 said the US-based drug maker is final stages to sign an agreement with Indian government to supply COVID-19 vaccines. “We are discussing with India govt, we are in final stages of finalising agreement,” Bourla said at the 15th annual BioPharma & Healthcare Summit,…

Read more: Pfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt

Pfizer says won’t make exception for India in its global approach for vaccine supply

Representative image Pfizer remains committed to work with the government of India to bring its COVID-19 vaccine to the country, but its approach wouldn’t change for India, the company said on June 22. “Our frameworks in India are consistent with those anywhere in the world where our COVID-19 vaccine is…

Read more: Pfizer says won’t make exception for India in its global approach for vaccine supply

Explained | What Phase 3 data submission of Covaxin means, how close is it to WHO approval, and comparison with other jabs

File image of the Covaxin COVID-19 vaccine The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO), on June 22, approved the Phase-3 trial efficacy data of Bharat Biotech’s COVID-19 vaccine, Covaxin. The data shows 77.8 percent efficacy, CNBC-TV18 reported. The Phase 3 trials were conducted on…

Read more: Explained | What Phase 3 data submission of Covaxin means, how close is it to WHO approval, and comparison with other jabs

Exclusive | SII focused on local vaccine demand, may export Covishield towards year end

Coronavirus Serum Institute of India, the world’s largest vaccine maker by volume, is currently focused on catering to domestic demand for COVID-19 vaccines even as government officials hinted at a possible easing of export restrictions. Serum Institute may start sending vaccines to other countries and COVAX, possibly by the end…

Read more: Exclusive | SII focused on local vaccine demand, may export Covishield towards year end

Honeywell launches authentication tech to prevent counterfeit pharma drugs

Representative image Honeywell on Monday announced digital authentication technology for the pharmaceutical industry in response to the growing menace of counterfeit products. An acute shortage of drugs to treat symptoms of COVID-19 has led to increased circulation of counterfeit medicines in recent times, a company statement said. It added that…

Read more: Honeywell launches authentication tech to prevent counterfeit pharma drugs

India auto hub lets car plants run at full capacity despite few vaccinations

India’s southern Tamil Nadu state, known for its flourishing automobile industry, on Sunday allowed some industrial units including those of global automakers in and around capital city Chennai to operate at 100% capacity. Car factories, including those of Renault-Nissan, Hyundai and Ford, can operate with full workforces in India’s automaking…

Read more: India auto hub lets car plants run at full capacity despite few vaccinations

Step up vaccination, implement public health measures rigorously, says WHO

CII president T V Narendran suggests measured opening up of activities to avoid new COVID wave

With COVID-led disruptions behind, Mahindra Logistics eyes sharp business growth in H2 FY22

Automakers initiate production ramp-up with easing of COVID restrictions in states

New software developed to help identify patients requiring ventilator support: Govt

COVID-19 deals new blow to foreign carmakers’ Indian dream

IDFC FIRST Bank offers four times annual CTC, salary continuation for two years to corona affected employees' families: MD

Fortis says only 1% of its workforce who received two COVID-19 jabs required ICU/ventilator support

OTHER NEWS